INDUSTRY NEWS

NICE GUIDANCE WELCOMED

Allergan plc has welcomed the publication of NICE guidance recommending the use of OZURDEXÂ® (dexamethasone 0.7mg intravitreal implant in applicator) for an important group of patients with diabetic macular oedema (DME).

â€œThis guidance from NICE confirms the value of OZURDEXÂ® as a treatment for DME, and supports its use as a clinically relevant and cost effective option for patients with this condition,â€ said Sara Vincent, Senior Vice President and Allergan UK Country Manager. www.allergan.com

Latest Articles

Thinking Beyond Optics: Diversity, Equity, and Inclusion (DEI) and Unconscious Bias in Ophthalmology

Beyond Sight: A Clearer Vision for Equity in Ophthalmology

Refractions of Bias: Seeing DEI Clearly in Ophthalmology

Happy Patients, Higher Volumes

Digitalisation reduces errors and saves time, making a surgeon’s life easier.

Addressing Postoperative Visual Complications

Managing aberrations after laser refractive surgery requires a multi-layered approach.

3D Printing Helps Transform Ukrainian Eye Care

The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.

Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation

Emerging Microbial Trends That Could Affect Your Practices

A triptych of challenges paints a concerning picture for ophthalmologists across the globe.

Improving Outcomes with Laser-Assisted Surgery

Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.

Could the Corneal Transplant Pool Increase?

Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.